Señales en vivo de ALVAL.PA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 abr 2024 @ 11:35):

Stats
Volumen de hoy	49 465.00
Volumen promedio	29 937.00
Capitalización de mercado	64.85M
EPS	€0 ( 2024-04-28 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-6.97
ATR14	€0.0150 (0.37%)

Volumen Correlación

Largo: -0.03 (neutral)

Corto: 0.33 (neutral)

Signal:(47.568) Neutral

Valbiotis SA Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Valbiotis SA Correlación - Moneda/Commodity

0.84
( strong )

0.80
( moderate )

0.00
( neutral )

0.64
( weak )

0.49
( neutral )

-0.16
( neutral )

Valbiotis SA Finanzas

Annual	2023
Ingresos:	€4.73M
Beneficio Bruto:	€2.00M (42.26 %)
EPS:	€-0.590

FY	2023
Ingresos:	€4.73M
Beneficio Bruto:	€2.00M (42.26 %)
EPS:	€-0.590

FY	2022
Ingresos:	€785 000
Beneficio Bruto:	€767 000 (97.71 %)
EPS:	€-1.220

FY	2021
Ingresos:	€2.05M
Beneficio Bruto:	€1.63M (79.64 %)
EPS:	€-0.0828

Financial Reports:

No articles found.

Valbiotis SA

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.